Regeneron Reports Third Quarter 2018 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Regeneron Pharma (REGN) PT Raised to $315 at Barclays
November 7, 2018 7:34 AM ESTBarclays analyst Geoff Meacham raised the price target on Regeneron Pharma (NASDAQ: REGN) to $315.00 (from $305.00) while maintaining a Underweight rating following the company's 3Q earnings report.
Meacham thought Regenerons 3Q results were very good (+$22M top-line; +$0.70 bottom-line), and while Barclays continues to... More
Regeneron (REGN) Tops Q3 EPS by 69c, Revenues Beat
November 6, 2018 6:37 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $5.87, $0.69 better than the analyst estimate of $5.18. Revenue for the quarter came in at $1.66 billion versus the consensus estimate of $1.64 billion.
Third quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 7% to $1.02 billion versus third quarter 2017, and third quarter 2018 EYLEA global net sales(1) increased 11% to $1.68 billion versus third quarter 2017U.S. launch of Libtayo® (cemiplimab-rwlc) Injection for the... More